Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with some patients having a slow progression and others an accelerated clinical and functional decline. This study aims to clinically characterize the type of progression in IPF and to investigate the pathological basis that might account for the observed differences in disease behavior. Clinical and functional data were analyzed in 73 IPF patients, followed long-time as candidates for lung transplantation. The forced vital capacity (FVC) change/year (< or ≥10% predicted) was used to define "slow" or "rapid" disease progression. Pathological abnormalities were quantified in the explanted lung of 41 out of 73 patients undergoing lung transplantation. At diagnosis, slow progressors (n = 48) showed longer duration of symptoms and lower FVC than rapid progressors (n = 25). Eleven slow and 3 rapid progressors developed an acute exacerbation (AE) during follow-up. Quantitative lung pathology showed a severe innate and adaptive inflammatory infiltrate in rapid progressors, markedly increased compared to slow progressors and similar to that observed in patients experiencing AE. The extent of inflammation was correlated with the yearly FVC decline (r = 0.52, p = 0.005). In conclusion an innate and adaptive inflammation appears to be a prominent feature in the lung of patients with IPF and could contribute to determining of the rate of disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008959 · Cited by 203
Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190 · cited 1×
“In this context, it is of interest to note that autoantibodies to heat shock protein 70 [15] and periplakin [23], which have been identified in serum and bronchoalveolar lavage of patients with IPF, have been reported to be associated with a more severe disease, further supporting the presence of an autoimmune respons…”
BackgroundIdentification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis
Taillé, C., Grootenboer-Mignot, S., Boursier, C., Michel, L., Debray, M.-P., Fagart, J., Barrientos, L., Mailleux, A., Cigna, N., Tubach, F., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0076oc · Cited by 120 · cited 1×
“In this context, it is of interest to note that autoantibodies to heat shock protein 70 [15] and periplakin [23], which have been identified in serum and bronchoalveolar lavage of patients with IPF, have been reported to be associated with a more severe disease, further supporting the presence of an autoimmune respons…”
Background
Cited by
Senescence and aging: Causes, consequences, and therapeutic avenues
McHugh, D., & Gil, J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708092 · Cited by 1,233
“The detrimental role for chronic inflammation during aging is further supported by clinical data (Libby, 2002; Brunt et al., 2009; Dinarello et al., 2010; Balestro et al., 2016).”
BackgroundZhu, Y., Liu, X., Ding, X., Wang, F., & Geng, X. (2019) · Biogerontology · doi:10.1007/s10522-018-9769-1 · Cited by 255
Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis
Li, F. J., Surolia, R., Li, H., Wang, Z., Kulkarni, T., Liu, G., de Andrade, J. A., Kass, D. J., Thannickal, V. J., Duncan, S. R., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700473 · Cited by 85
Inhibition of NF-κB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis
Jaffar, J., Glaspole, I., Symons, K., & Westall, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111471 · Cited by 45
Metadata
- Authors
- Balestro, E., Calabrese, F., Turato, G., Lunardi, F., Bazzan, E., Marulli, G., Biondini, D., Rossi, E., Sanduzzi, A., Rea, F., Rigobello, C., Gregori, D., Baraldo, S., Spagnolo, P., Cosio, M. G., & Saetta, M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-09
- Volume
- 11
- Issue
- 5
- Pages
- e0154516
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2346365634
- Cited by
- 98
- References
- 10
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1371/journal.pone.0154516
- The paper
- Balestro, E., Calabrese, F., Turato, G., Lunardi, F., Bazzan, E., Marulli, G., Biondini, D., Rossi, E., Sanduzzi, A., Rea, F., Rigobello, C., Gregori, D., Baraldo, S., Spagnolo, P., Cosio, M. G., & Saetta, M. (2016). Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0154516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.